ARKAY Therapeutics, LogoFollow Us:LinkedIn
Phone Icon (609) 362-6818

RK-01: PoC in a Translational Mouse Model 

Study results were presented at the 76th Scientific Sessions of the American Diabetes Association, June 10-14, New Orleans, LA.
Anti-inflammatory 'Beta-cell centric' Drug Combination Lowers Non-fasting and Fasting Blood Glucose Levels and Improves Glucose Tolerance in C57BL/6J DIO M
ice With Insulin Resistance and Beta-cell Dysfunction*

* Study was performed with USP Grade, finished product-ready APIs

"Looks promising"
Marc Donath, MD
Head of the clinic for Endocrinology, Diabetes, and Metabolism
Department of Biomedicine
University Hospital, Basel, Switzerland
Expert in the role of pancreatic islet inflammation in Type 2 diabetes

Validation of ARKAY's Product Concept

Human PoC of Treating Type 2 Diabetes with Valsartan


Glycemic Control with Valsartan

Dual Combination of Valsartan and Sacubitril lowered A1c, persistenly maintained lowered A1c and more importantly, 29% fewer patients initiated insulin therapy over a period of 3 years.

Valsartan monotherapy has also been shown to improve beta-cell function and insulin sensitivity


Human PoC of Treating Type 2 Diabetes with Celecoxib

Dual combination of Celecoxib and Glimepiride improved beta-cell function, glycemic, inflammatory, and lipid parameters better than Glimepiride alone in obese Type 2 diabetes patients.

"Impressive - full speed ahead!"
Stan Schwartz, MD

Nationally and internationally known expert in diabetes and a champion of 'Beta-cell-centric' therapies

Glycemic Control with Celecoxib

Cardiovascular (CV) Safety of Celecoxib for Chronic Use

 Results from the landmark PRECISION trials indicate that CV, GI and renal risks associated with longterm use of Celecoxib is low and it is safer than other NSAIDs such as Naproxen and Ibuprofen in patients with CV risk. Clinical trial results were presented at the Scientific Sessions of the American Heart Association, November 12-16, 2016 in New Orleans, LA

"After the withdrawal of rofecoxib, there ensued a rush to judgement about the cardiovascular safety of of Cox-2 inhibitors. Fueled by the controversy and some experts commentary used observational data, small RCTs and theoretical concerns to "confirm" what they expected. The PRECISION trial demonstrates the hazards inherent in prejudgement about the risks and benefits of therapies based upon expectations and indirect methods. These findings serve as an important warning to the medical community that we may arrive at erroneous conclusion when we fail to follow a systematic and unbiased approach to scientific and public health questions"

Steven Nissen, MD
Principal Investigator, PRECISION Trial
Chairman, Cardiovascular Medicine
The Cleveland Clinic Foundation
November 13, 2016 AHA's Scientific Sessions, New Orleans, LA

PRECISION Trial Research Paper

Stop Diabetes

Why Now Is the Time to Partner and Collaborate

Currently, there are no anti-inflammatory 'Beta cell-centric' therapies on the market. This is why the opportunity to capitalize on this cutting-edge medicine is so great.

Our lead combination product, RK-01 was efficacious and safe in the preclinical PoC studies performed using C57BL/6J DIO (Diet-induced obesity) mice with pancretic beta-cell dysfunction and insulin resistance*.

More importantly, ARKAY's product concept has been validated by human PoC for using dual combinations that contain Valsartan or Celecoxib for treating Type 2 diabetes. 

ARKAY Therapeutics has created an innovative platform for advancing anti-inflammatory 'Beta-cell-centric' therapies by filing U.S. and PCT patent applications "Formulations and Methods for Treatment of Metabolic Syndrome” (Publication Numbers: US 2016/0067217A1, US 2016/0213694 A1 & WO 2016/040462). They describe in detail over 60 formulations and methods for treating Type 2 diabetes, Prediabetes and metabolic disease-related disorders. 

Gain a more in-depth view of our organization and the kinds of medication we’re creating by clicking here.

*ARKAY has been operating as a virtual company by collaborating with leading CROs

Type 2 Diabetes by the Numbers

Type 2 diabetes is a pandemic and the patient population is expected to double to over 600 million world-wide and over 40 million in the United States by 2040 (IDF, Facts & Figures). The prevalence of Prediabetes is three times that of Type 2 diabetes.  In 2012, 86 million Americans age 20 or older had prediabetes (American Diabetes Association). The global Type 2 Diabetes market will grow from $20.4 billion in 2012 to $38.8 billion in 2019 (Global Business Intelligence). The global market for Metabolic Syndrome is estimated to be $72.4 billion by 2018 (Biovision). 


Diabetes-Related Complications

Understand Our Company

As a savvy investor, we understand that you’re not going to take a risk without knowing every past, present, and future aspect of our biopharmaceutical company. That’s why we invite you to get to know us and gain a sense of our potential.

Upon request, we provide the Executive Summary and the Business Plan that will cover all the information you need to make a smart, well-informed investment decision. Take a moment to read about our founder, president and CEO, Dr. Ravi Kumar by clicking here.

ARKAY has developed a low-to-moderate risk business plan to develop and commercialize an innovative product that differentiates clinically and mechanistically for an pandemic with an enormous market potential in 4 to 5 years with a potential exit strategy in 2 to 3 years.